Stealth BioTherapeutics Provides Update On Clinical Stage Rare Disease Programs; Co. Reports ‘Early data from a study of elamipretide and an exon-skipping phosphorodiamidate morpholino oligomer increased dystrophin expression in muscle to almost twice the levels observed following stand-alone treatment with the PMO’